Dencichine Preparation for Thrombocytopenia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Thrombocytopenia, such as platelet transfusions and medications like interleukin-11 and thrombopoietin, are limited by short preservation time, high cost, potential blood-borne infections, and adverse reactions, necessitating a safer and more effective therapeutic option.
Innovation Solution
Dencichine, a non-protein amino acid with hemostatic properties, is developed into an oral or injectable preparation to treat Thrombocytopenia by increasing platelet count and improving thrombocyte aggregation, offering a safer alternative with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If platelet transfusion is used to treat Thrombocytopenia, then platelet count increases effectively, but preservation time is short and blood supply is limited
Solution Approach 1:
The patent uses recombinant human thrombopoietin, a synthetic protein that can be produced indefinitely through biotechnology, replacing the short-living platelet transfusion approach. This allows for sustained platelet production without the limitations of blood supply and preservation time.
Solution Approach 2:
The patent administers thrombopoietin before chemotherapy treatment to pre-stimulate platelet production, ensuring adequate platelet levels are maintained throughout the chemotherapy course rather than reacting to platelet depletion after damage occurs.
2Quantity of substance
If platelet transfusion is used to treat Thrombocytopenia, then platelet count increases effectively, but cost is high and blood-borne infections are possible
Solution Approach 1:
The patent replaces expensive, infection-risk-prone platelet transfusions with a recombinant protein therapy that can be produced in controlled laboratory conditions, eliminating blood-borne infection risks and reducing long-term costs despite higher initial drug expense.
Solution Approach 2:
The patent introduces thrombopoietin as an intermediary substance that stimulates the body's own platelet production mechanisms, rather than directly transfusing platelets. This indirect approach avoids the hazards associated with direct blood product administration.
3Reliability
If interleukin-11 and thrombopoietin are used to treat Thrombocytopenia, then curative effect is preferable, but adverse reactions occur and price is expensive
Solution Approach 1:
The patent optimizes the dosage parameters and administration timing of thrombopoietin to achieve effective platelet stimulation while minimizing adverse reactions. By carefully controlling the concentration and schedule, the therapeutic window is maximized.
Solution Approach 2:
The patent administers thrombopoietin prophylactically before chemotherapy-induced thrombocytopenia develops, preventing the severe platelet drops that would trigger adverse reactions from aggressive rescue treatments, thereby reducing overall side effect burden.
Data Source
AI summary
Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects.